单细胞追踪揭示黑色素瘤 TIL 治疗过程中肿瘤反应性 T 细胞的可塑性
Single-cell tracking reveals tumor-reactive T cell plasticity during melanoma TIL therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
TIL（肿瘤浸润淋巴细胞）治疗的进展与前景
英文原题：Advances and prospects in tumor infiltrating lymphocyte therapy.
查看英文原题
Advances and prospects in tumor infiltrating lymphocyte therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
过继T细胞疗法（ACT）中的TIL（肿瘤浸润淋巴细胞）疗法已在多种癌症中引起持久消退，这得益于T细胞的持续存在、临床活性、客观缓解持续时间及安全性。TIL由针对异质性肿瘤抗原的多克隆效应T细胞组成，因此为肿瘤治疗提供了有前景的途径。此外，在体外扩增TIL可使其脱离抑制性肿瘤微环境。尽管TIL疗法流程已取得显著进展，包括TIL分离、改造、扩增及回输患者以靶向肿瘤，但优化策略仍在持续推进，以克服流程复杂、TIL谱系分化状态选择有限以及TIL向肿瘤充分迁移等问题。本综述总结TIL疗法的当前进展，提出基于问题的优化策略，并展望下一代TIL疗法作为增强细胞免疫疗法的潜在途径。
展开英文摘要原文
Tumor-infiltrating lymphocyte (TIL) therapy in adoptive T-cell therapy (ACT) has already caused durable regression in a variety of cancer types due to T-cell persistence, clinical activity, and duration of objective response and safety. TILs are composed of polyclonal effector T-cells specific to heterogenetic tumor antigens, reasonably providing a promising means for tumor therapy.
In addition, their expansion in vitro can release them from the suppressive tumor microenvironment. Even though significant advances have been made in the procedure of TIL therapy, from TIL isolation, modification, expansion, and infusion back to the patient to target the tumor, strategy optimization is always ongoing to overcome drawbacks such as a complex process, options for the lineage differentiation status of TILs, and sufficient trafficking of TILs to the tumor.
In this review, we summarize the current advances of TIL therapy, raise problem-based optimization strategies, and provide future perspectives on next-generation TIL therapy as a potential avenue for enhancing cell-based immunotherapy.
论文信息
- 作者
- Qiu X、Li S、Fan T、Zhang Y、Wang B、Zhang B、Zhang M、Zhang L
- 第一作者单位
- The Department of Immunology, School of Basic Medicine, Qingdao University, Qingdao, Shandong, China.China
- 通讯作者单位
- The Department of Immunology, School of Basic Medicine, Qingdao University, Qingdao, Shandong, China. 343918320@qq.com.China
- 文献类型
- 综述
- 期刊
- Discover oncology2024 Nov 8
- 原文标识
- PubMed 39514075 · DOI 10.1007/s12672-024-01410-5
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →